Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Immutep Limited before investing.

In this article, we go over a few key elements for understanding Immutep Limited’s stock price such as:

• Immutep Limited’s current stock price and volume
• Why Immutep Limited’s stock price changed recently
• Upgrades and downgrades for IMMP from analysts
• IMMP’s stock price momentum as measured by its relative strength

About Immutep Limited (IMMP)

Before we jump into Immutep Limited’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Want to learn more about Immutep Limited’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Immutep Limited.

Immutep Limited’s Stock Price as of Market Close

As of December 09, 2025, 4:00 PM, CST, Immutep Limited’s stock price was $2.250.

Immutep Limited is down 0.88% from its previous closing price of $2.270.

During the last market session, Immutep Limited’s stock traded between $2.110 and $2.360. Currently, there are approximately 956.24 million shares outstanding for Immutep Limited.

Immutep Limited’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Immutep Limited Stock Price History

Immutep Limited’s (IMMP) price is currently up 10.84% so far this month.

During the month of December, Immutep Limited’s stock price has reached a high of $3.530 and a low of $1.670.

Over the last year, Immutep Limited has hit prices as high as $2.710 and as low as $1.320. Year to date, Immutep Limited’s stock is up 3.69%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Immutep Limited Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 08, 2025, there were analysts who downgraded Immutep Limited’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Immutep Limited’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Immutep Limited’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Immutep Limited’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Immutep Limited (IMMP) by visiting AAII Stock Evaluator.

Relative Price Strength of Immutep Limited

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 08, 2025, Immutep Limited has a weighted four-quarter relative price strength of -2.01%, which translates to a Momentum Score of 51 and is considered to be Average.

Want to learn more about how Immutep Limited is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Immutep Limited Stock Price: Bottom Line

As of December 9, 2025, Immutep Limited’s stock price is $2.250, which is down 0.88% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Immutep Limited stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.